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BACKGROUND: Meta-analyses of the published literature indicate that about 9% of gastric cancers contain Epstein-Barr virus (EBV), with
consistent and significant differences by sex and anatomic subsite. This study aimed to identify additional determinants of EBV
positivity and their joint effects.
METHODS: From 15 international populations with consistent laboratory testing for EBV, we pooled individual-level data for 5081
gastric cancer cases including information on age, sex, subsite, histologic type, diagnostic stage, geographic region, and period of
diagnosis. First, we combined population-specific EBV prevalence estimates using random effects meta-analysis. We then aggregated
individual-level data to estimate odds ratios of EBV positivity in relation to all variables, accounting for within-population clustering.
RESULTS: In unadjusted analyses, EBV positivity was significantly higher in males, young subjects, non-antral subsites, diffuse-type
histology, and in studies from the Americas. Multivariable analyses confirmed significant associations with histology and region. Sex
interacted with age (P¼0.003) and subsite (P¼0.002) such that male predominance decreased with age for both subsites. The
positivity of EBV was not significantly associated with either stage or time period.
CONCLUSION: Aggregating individual-level data provides additional information over meta-analyses. Distinguishing histologic and
geographic features as well as interactions among age, sex, and subsite further support classification of EBV-associated gastric cancer
as a distinct aetiologic entity.
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Gastric cancer is the second leading cause of cancer-related deaths
worldwide (Parkin et al, 2005). Chronic Helicobacter pylori infection
is considered to be the initiating factor in gastric carcinogenesis
(International Agency for Research on Cancer, 1994), although
human genetic polymorphisms and environmental factors also
modulate risk of neoplasia (Correa et al, 2006; Hamajima et al, 2006).
Epstein-Barr virus (EBV) is a ubiquitous infectious agent which
has been causally linked to the development of several malig-
nancies, including Burkitt’s lymphoma, immunosuppression-
related lymphoma, Hodgkin’s lymphoma, and nasopharyngeal
carcinoma (International Agency for Research on Cancer, 1997).
Although some cases of gastric adenocarcinoma harbour EBV
infection (Takada, 2000; Akiba et al, 2008), it remains unclear
whether the presence of EBV is a cause or a consequence of
neoplastic changes.
To expand on our recent meta-analysis of EBV prevalence in
gastric cancer (Murphy et al, 2009), we have conducted a pooled
analysis of individual-level data on variables for which the
published aggregate data were insufficient for meta-analysis. In
addition, we aimed to investigate whether EBV positivity is
modified by the joint effect of these determinants.
MATERIALS AND METHODS
Data sources
Over the past 10 years, one of us (SA) has participated in multiple
international collaborations assessing the presence of EBV in
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sgastric cancer tumours in Asia and Latin America. In general, these
studies followed a common protocol evaluating EBV infection by
EBV-encoded small RNA in situ hybridisation. In the present
reanalysis, we have combined individual-level data of 12 of these
studies from areas with differing risk profiles for gastric cancer
(Corvalan et al, 2001; Koriyama et al, 2001, 2004; Hao et al, 2002;
Kattoor et al, 2002; Carrascal et al, 2003; Lee et al, 2004; Anwar
et al, 2005; Herrera-Goepfert et al, 2005; Yoshiwara et al, 2005;
Campos et al, 2006; Abdirad et al, 2007). Since none of these
studies was conducted in North America or Europe, these
geographic areas were not represented in our analysis. We
included information on EBV status, sex, age at diagnosis,
geographic region, histologic type, anatomic subsite, diagnostic
stage, and year of diagnosis. Two of the identified studies
(Koriyama et al, 2001; Hao et al, 2002) reported findings from
more than one population group, and thus, data on 15 distinct
populations were analysed.
Statistical analyses
Given the limited sample size in some studies, EBV prevalence and
corresponding standard errors (s.e.) were calculated by the Wilson
method (Wilson, 1927) for each population, overall and separately
for the following five covariables: age at diagnosis (treated as a
continuous and as a categorical variable), sex (male vs female),
anatomic subsite (antrum vs other subsites; overlapping cases were
excluded), diagnostic stage (early vs advanced), and Lauren
histologic type (diffuse vs intestinal). The diffuse subtype included
the following Japanese histologic classifications: solid type poorly
differentiated adenocarcinoma (por1), non-solid type poorly
differentiated adenocarcinoma (por2), signet-ring cell carcinoma
(sig), and lymphepithelial-like carcinoma (LE). The intestinal
subtype included the following: well-differentiated type tubular
adenocarcinoma (tub1), moderately differentiated type tubular
adenocarcinoma (tub2), papillary adenocarcinoma (pap), and
mucinous adenocarcinoma (muc). Population-specific log odds
ratios (ORs) and 95% confidence intervals (CIs) of EBV positivity
were calculated for the same five covariables using standard
logistic regression models. Strata with no EBV-positive cases were
assigned an arbitrary prevalence of 1% to allow calculation of ORs
and for the subsequent meta-analysis.
Random effects meta-analysis (DerSimonian and Laird, 1986)
was used to pool overall log prevalence estimates, with s.e. (log
prevalence) calculated by the Delta-method as 1/prevalence s.e.
(prevalence), and to pool log ORs for covariables. Between study
heterogeneity was assessed using the I
2 and Q statistics, with
I
2 450% or PQo0.05 indicating heterogeneity (Deeks, 2002;
Higgins and Thompson, 2002).
To increase statistical precision, pooled ORs were also estimated
for aggregated data using logistic regression models that included
a random population-specific intercept. This approach avoided the
computational requirement for non-zero prevalence for all
subgroups. In addition to the covariables-listed above, we also
assessed the separate effects of geographic region (Americas vs
Asia), estimated national gastric cancer incidence rates in 2008
(o10, 10–19.9, and X20 cases per 100000 population; Ferlay et al,
2010), year of diagnosis, and decade of birth. Year of diagnosis
was treated alternatively as a continuous or categorical (p1959,
1960–1969, 1970–1979, 1980–1989, and X1990) variable. Decade
of birth was also treated as either continuous or categorical
(p1919, 1920–1929, 1930–1939, 1940–1949, 1950–1959, and
X1960). Additionally, age, year of diagnosis, and decade of birth
were tested for non-linear associations with EBV positivity by
including the squared terms of the variables in the respective
models. Two-sided P-values for associations o0.05 were con-
sidered statistically significant. Pooled ORs for the meta-analytic
and aggregated approaches were generally similar, so only the
aggregated estimates are presented.
To assess interactions and evaluate confounding, we performed
multivariable aggregated analysis, excluding the terms for decade
of birth and national incidence due to collinearity with age and
period and with region, respectively. To evaluate effect modifica-
tion, we generated cross-product terms for the six pairwise
combinations of the four variables significantly associated with
EBV positivity (i.e., age at diagnosis, sex, anatomic subsite, and
histologic type). In the final models, age at diagnosis was treated as
a continuous variable and adjustments were included for stage,
decade of diagnosis, and geographic region. Wald w
2-tests were
used to assess interaction terms, with P-values corrected for
multiple comparisons of o0.0083 (0.05/6) considered statistically
significant. Estimated parameters from the final regression model
were used to calculate age-specific prevalence of EBV positivity by
sex and anatomic subsite, as well as age- and subsite-specific ORs
of EBV positivity for males compared with females. All statistical
analyses were performed in Stata 10.0 (Stata Corp, College Station,
TX, USA).
RESULTS
A total of 5081 gastric cancer cases from 15 different populations
contributed to these analyses (Table 1). The meta-analytic
estimated prevalence of EBV positivity was 7.7% overall (95%
CI: 6.1–9.8), with high heterogeneity among studies (I
2¼77.5%,
PQo0.001; Figure 1).
In unadjusted analyses (Table 2), the following association
patterns emerged: (a) tumours in young subjects were more likely
to be EBV positive than those in older subjects, (b) tumours in
males were more than twice as likely to be EBV positive than
tumours in females, (c) non-antral tumours were more likely to be
EBV positive than those arising in the antrum, (d) diffuse-type
tumours were almost twice as likely to be EBV positive than
tumours of intestinal histology, and (e) EBV prevalence was
similar in early and advanced tumours. Furthermore, EBV
positivity did not significantly differ by decade of birth (ORs for
comparison with 1910s or earlier: 1.3 for 1920s, 1.1 for 1930s, 1.2
for 1940s, 1.5 for 1950s, and 1.6 for 1960s or later) or decade of
diagnosis (ORs using 1990 or later as referent: 0.7 for p1959, 1.2
for 1960s, 1.0 for 1970s, and 1.3 for 1980s). However, EBV
positivity was significantly higher for studies conducted in the
Americas as compared with those in Asia (OR: 1.7, 95% CI:
1.1–2.7) and marginally lower in countries with gastric cancer
incidence rates o10 or X20 cases per 100000 population as
compared with 10–19.9 cases per 100000 population (OR: 0.5, 95%
CI: 0.3–1.0 and OR: 0.7, 95% CI: 0.4–1.1, respectively). Inclusion
of squared terms for age, decade of birth and period did not
significantly improve the fit of models with linear terms for these
variables.
The multivariable aggregated analyses identified four pairwise
interactions at the Po0.05 level: sex and anatomic subsite
(P-value¼0.002), age and sex (P-value¼0.003), age and anatomic
subsite (P-value¼0.011), and age and histologic type
(P-value¼0.013), with only the first two statistically significant
as corrected for multiple comparisons. Prevalence of EBV
positivity decreased with age among men, more steeply for
tumours localised to the antrum than for those localised to other
anatomic subsites (Figure 2). In contrast, there was no significant
variation by age among women, although tumours in non-antral
subsites had slightly higher EBV prevalence. In terms of the risk
estimates, male predominance decreased with age for both subsites
(Table 3).
In a final model that included the two significant interactions,
we confirmed the associations of EBV positivity with diffuse-type
histology (OR: 2.0, 95% CI: 1.5–2.6) and with studies from the
Americas (OR: 2.3, 95% CI: 1.5–3.7). Differences by diagnostic
stage or period of diagnosis were not statistically significant.
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sDISCUSSION
We analysed individual-level participant data on 5081 subjects
with gastric cancer from international studies we previously
conducted with a consistent approach to EBV testing. As compared
with our individual reports, the present reanalysis had greater
statistical power for robust observations. The magnitude of the
observed pooled prevalence (7.7%; 95% CI: 6.1–9.8%) and the
degree of heterogeneity among our studies were similar to that
reported in previous meta-analyses of the published literature (Lee
et al, 2009; Murphy et al, 2009; Li et al, 2010). Moreover, this
pooled analysis also evaluated associations with additional
variables that were not included in prior meta-analyses, provided
adjusted estimates, and was able to examine interactions.
Previous reports have indicated that EBV-positive gastric
tumours tend to be proximally located, and account for a greater
proportion of cases in males than in females (Murphy et al, 2009).
However, few studies have found variation by age (Chang et al,
2003; van Beek et al, 2004). With our large data set, we found that
EBV positivity varies jointly by age, sex, and anatomic subsite,
interactions that may be obscuring a main effect of age. The young
predominance in males and the countervailing age trend in females
suggest the importance of occupational, hormonal, and/or lifestyle
factors in the aetiology of EBV-associated gastric cancer.
H. pylori infection preferentially colonises the antrum
(Martı ´n-de-Argila et al, 1997), so the contrasting localisation
of EBV-positive gastric cancer to non-antral subsites suggests
possible antagonism between the two infectious agents. An in vitro
study directly examining this interaction found that reactive
products from H. pylori infection trigger EBV reactivation
in latently infected gastric epithelial cells (Minoura-Etoh
et al, 2006).
Two reports encompassed in the present analysis have examined
variation in EBV prevalence of gastric tumours over time or birth
Note: weights are from random effects analysis
Overall  (I
2 = 77.5%, P<0.001)
Yoshiwara et al (2005)
Hao et al (2002)
Campos et al (2006)
Hao et al (2002)
Kattoor et al (2002)
Abdirad et al (2007)
Koriyama et al (2004)
Authors
Herrera-goepfert et al (2005)
Anwar et al (2005)
Koriyama  et al (2001)
Koriyama  et al (2001)
Corvalan et al (2001)
Lee et al (2004)
Koriyama  et al (2001)
Carrascal et al (2003)
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Colombia
China (Southern)
India
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Brazil (Caucasians)
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Brazil (Blacks)
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7.7 (6.1, 9.8)
4.3 (2.4, 7.7)
6.1 (3.5, 10.8)
11.4 (8.6, 15.2)
9.1 (5.9, 14.1)
4.7 (2.5, 8.5)
3.3 (1.7, 6.3)
6.6 (5.6, 7.8)
7.3 (5.0, 10.7)
1.9 (0.3, 13.4)
4.7 (2.3, 9.7)
10.3 (6.2, 17.3)
6.9 (5.2, 9.2)
16.0 (6.5, 39.3)
13.0 (8.9, 19.0)
6.21
8.75
5.70
9.57
7.91
1.26
8.72
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(95% CI)
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100.00
6.25
7.40
5.99
%
Weight
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Figure 1 Estimated prevalence (95% CIs) of EBV positivity in gastric cancers from 15 populations.
Table 1 Selected characteristics of the study populations
Tumour characteristics (%)
a
Country
Authors, year
of publication
GC incidence rate
in both sexes,
ASR (W)
b Sample size
Study
period
Age in
years,
mean (s.d.)
%
Males
Antrum
location
Diffuse
type
c
Early
stage
Brazil Koriyama et al (2001) 10.9 126 (Caucasians) 1949–1988 54 (12) 67 89 48 8
25 (Blacks) 1949–1988 49 (13) 72 94 42 8
149 (Japanese Brazilians) 1949–1988 56 (12) 66 75 53 10
Chile Corvalan et al (2001) 17.9 185 1993–1997 61 (13) 65 35 38 22
China Hao et al (2002) 29.9 180 (Northern) 1991–2000 59 (12) 73 35 50 5
198 (Southern) 1987–2000 58 (12) 63 53 57 4
Colombia Carrascal et al (2003) 17.4 177 1996–1999 59 (14) 61 55 49 4
Campos et al (2006) 17.4 368 2000–2003 61 (14) 63 61 45 19
India Kattoor et al (2002) 3.8 215 1997–1999 60 (11) 75 49 41 No data
Iran Abdirad et al (2007) 15.6 272 1969–2004 57 (11) 72 49 25 1
Japan Koriyama et al (2004) 31.1 1927 1976–1995 62 (12) 64 50 43 37
Korea Lee et al (2004) 41.4 621 1995–1996 55 (13) 67 49 53 32
Mexico Herrera-Goepfert et al (2005) 7.9 330 1980–2000 58 (15) 52 48 63 4
Pakistan Anwar et al (2005) 6.3 52 1996–2002 50 (15) 71 64 62 No data
Peru Yoshiwara et al (2005) 21.2 256 1994–2001 65 (13) 49 51 50 14
All — — 5081 1949–2004 60 (13) 64 51 46 24
Abbreviations: ASR¼age-standardised rate; GC¼gastric cancer; s.d.¼standard deviation; W¼World.
aExcluding missing.
bNational ASR as cases per 100000 population
(Ferlay et al, 2010).
cThe diffuse subtype included the Japanese classifications por1, por2, sig, and LE, and the intestinal subtype included tub1, tub2, pap, and muc.
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scohort. Abdirad et al (2007) noted a cluster of EBV positivity in
cancers of a specific birth cohort (Iranians born 1928–1930).
However, Herrera-Goepfert et al (2005) found similar EBV
prevalence in Mexican cases diagnosed during 1980–1989 as
compared with those diagnosed in 1990–2000. Our pooled
analysis, using data on cases diagnosed between 1949 and 2004,
did not find consistent changes over time.
An inverse relationship has previously been suggested between
the background population incidence of gastric cancer and EBV
prevalence in the tumours (Murphy et al, 2009). In our data, EBV
positivity was similar for cases in countries with high and low
background incidence, but significantly higher in tumours from
the Americas as compared with those from Asia. While we cannot
distinguish their independent effects, EBV-positive gastric cancer
may differ by geographic region rather than with background
incidence per se.
While results from previous meta-analyses disagreed regarding
associations with histologic subtype (Lee et al, 2009; Murphy et al,
2009; Li et al, 2010), we found a higher EBV prevalence in diffuse-
type tumours. Histologic classification differs among pathologists
(Borchard, 1990) and our pooled analysis may have had more
Table 2 Odds ratios of gastric cancer EBV positivity for age, sex, anatomic subsite, histologic type, and clinical stage of diagnosis
OR of EBV positivity (95% CI)
Age groups (years)
Population
Overall
EBV(+) p35 36–45 46–55 56–65
465
(reference)
Age effect
per year
Sex
(male)
Subsite
(non-
antrum)
Histologic
type
a
(diffuse)
Stage at
diagnosis
(advanced)
Brazil
Caucasians 10.3 2.1 2.0 1.3 3.7 1.0 1.0 3.0 5.1
b 2.7 0.4
Blacks 16.0 1.0 0.4 1.5 0.03
c 1.0 0.9 28.6
c 0.1
c 1.5 21.1
c
Japanese Brazilians 4.7 7.8 3.3 1.6 0.3
c 1.0 0.5
b 0.4 1.0 2.3 5.8
c
Chile 16.8 1.0 1.2 1.0 1.6 1.0 1.00 1.6 3.9
b 4.4
b 1.0
China
Northern 6.1 0.2
c 0.8 3.3 0.7 1.0 0.9 4.0 1.5 1.3 6.7
c
Southern 9.1 6.9 2.9 2.0 1.3 1.0 0.7
b 2.2 4.4
b 12.2
b 7.6
c
Colombia
Carrascal et al 13.0 1.8 2.9 2.4 0.9 1.0 0.7 3.5
b 3.3
b 1.2 15.8
c
Campos et al 11.4 2.2 1.1 1.9 2.2 1.0 0.9 2.8
b 1.6 2.5
b 1.2
India 4.7 10.5 1.2 1.6 1.7 1.0 0.8 6.6
c 6.1 3.6 No data
Iran 3.3 4.5 2.6 3.3 1.3 1.0 0.7 3.2 2.0 6.5
b 3.3
c
Japan 6.6 1.8 1.3 0.8 1.3 1.0 0.9 2.8
b 3.6
b 1.2 1.2
Korea 6.9 2.0 0.9 0.7 0.9 1.0 0.9 11.1
b 3.4
b 1.4 1.1
Mexico 7.3 0.1
c 0.1
c 0.6 0.8 1.0 1.8
b 1.1 1.9 2.4 0.5
Pakistan 1.9 1.0
c 10.0
c 1.0
c 1.0
c 1.0 0.6 8.3
c 1.0
c 0.2
c No data
Peru 4.3 0.2
c 1.4 2.7 0.3 1.0 0.9 1.3 2.9 1.8 0.7
Unadjusted
Pooled OR
1.8
(1.1–2.8)
1.2
(0.8–1.8)
1.2
(0.8–1.6)
1.2
(0.9–1.6)
1.0 1.0
(0.98–1.00)
2.5
(2.0–3.3)
2.8
(2.2–3.6)
1.8
(1.5–2.3)
1.1
(0.9–1.5)
I
2/PQ 0%/0.89 0%/0.89 0%/0.71 0%/0.86 17%/0.27 22%/0.21 0%/0.85 39%/0.1 0%/0.96
Abbreviations: CI¼confidence interval; OR¼odds ratio; EBV¼Epstein-Barr virus.
aThe diffuse subtype included the Japanese classifications por1, por2, sig, and LE, and the
intestinal subtype included tub1, tub2, pap, and muc.
bPo0.05.
c1% prevalence of EBV was assumed to allow calculation of population-specific ORs.
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Figure 2 Fitted age-specific prevalence of EBV positivity in gastric
tumours, by sex and anatomic subsite.
Table 3 Odds ratios (95% confidence intervals)
a of gastric cancer EBV
positivity for males compared with females, by anatomic subsite and age
Anatomic subsite
Antrum Non-antrum
Age in years
20 6.1 (2.1–17.9) 12.4 (4.6–33.4)
40 3.3 (1.6–6.6) 6.7 (3.7–12.1)
60 1.8 (1.1–2.9) 3.6 (2.4–5.3)
80 0.9 (0.5–1.8) 1.9 (1.0–3.6)
Abbreviation: EBV¼Epstein-Barr virus.
aEstimates adjusted for geographic region,
histologic type, diagnostic stage, and period of diagnosis.
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sconsistent laboratory methods and pathologic review than the
varied approaches in the published literature.
Although it has been suggested that EBV-positive gastric cancer
cases may have a better prognosis than EBV-negative cases,
previous individual reports are limited and somewhat inconsistent.
Recently, Song et al (2010) reported a survival advantage for
certain histologic subgroups of EBV-associated gastric cancer in a
large Korean series, but there was no significant survival advantage
for EBV-positive tumours overall. A meta-analytic review by Lee
et al (2009) including seven studies did not find associations with
the clinicopathologic prognostic indicators clinical stage, depth of
invasion, or lymph node metastasis. Our null finding for clinical
stage was consistent with this meta-analysis and, importantly, our
estimates were also adjusted for possible confounders.
Although the specific role of EBV in gastric carcinogenesis has
not yet been elucidated, several lines of evidence support its
aetiological significance. Epstein-Barr virus-positive gastric carci-
nomas exhibit uniform presence of monoclonal viral episomes in
the tumour cells (Ott et al, 1994). Epstein-Barr virus-positive
gastric carcinomas also display distinct clinical and genetic
features relative to EBV-negative tumours (zur Hausen et al,
2000; van Beek et al, 2004). In addition, some studies have found
elevated serum antibodies against viral capsid and nuclear
antigens preceding development of preneoplastic and neoplastic
gastric lesions (Levine et al, 1995; Schetter et al, 2008).
Histologic specificity and geographic variation suggest that
EBV-positive gastric cancer is a distinct entity. The pairwise
interactions that we found among age, sex, and anatomic subsite
are novel and should be explored further. Our findings reveal a
complex interplay of factors influencing EBV’s presence in gastric
tumours and may provide important clues to understanding its
aetiologic significance.
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